{"disease":{"id":"peripheral-neuropathy-in-breast-cancer-patient","name":"peripheral neuropathy in breast cancer patient"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05802342","title":"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06711978","title":"Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Pusan National University Yangsan Hospital","has_results":false},{"nct_id":"NCT02795572","title":"Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}